Expanded AVISE® CTD trailing twelve-month average selling price
Reduced Adjusted EBITDA loss for first three quarters of 2024
Revenue in line with expectations, excluding one-time adjustments
Exagen Inc. Reports Third Quarter 2024 Results
EXAGEN INC
NASDAQ:XGN (2/11/2025, 5:20:02 PM)
After market: 4.56 -0.23 (-4.8%)4.79
-0.01 (-0.21%)
XGN Latest News and Analysis
7 days ago - ChartmillTuesday's session: top gainers and losersStay up-to-date with the latest market trends in the middle of the day on Tuesday. Explore the top gainers and losers during today's session in our detailed report.
